DK2040548T3 - Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase - Google Patents

Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase

Info

Publication number: DK2040548T3
Authority: DK; Denmark
Prior art keywords: glucocerebrosidase; activity; increasing; beta; neurological disorders
Prior art date: 2006-06-23

Application number

DK07812295T

Other languages

English (en)

Inventor

Brandon Wustman

Original Assignee

Amicus Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-23

Filing date

2007-06-25

Publication date

2012-08-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38834440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2040548(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-25 Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc

2012-08-13 Application granted granted Critical

2012-08-13 Publication of DK2040548T3 publication Critical patent/DK2040548T3/da

Links

102000004547 Glucosylceramidase Human genes 0.000 title abstract 7
108010017544 Glucosylceramidase Proteins 0.000 title abstract 7
238000000034 method Methods 0.000 title abstract 4
230000000694 effects Effects 0.000 title abstract 3
208000012902 Nervous system disease Diseases 0.000 title abstract 2
208000025966 Neurological disease Diseases 0.000 title abstract 2
108010006519 Molecular Chaperones Proteins 0.000 abstract 2
210000003169 central nervous system Anatomy 0.000 abstract 2
230000000144 pharmacologic effect Effects 0.000 abstract 2
102000005431 Molecular Chaperones Human genes 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000035772 mutation Effects 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Hydrogenated Pyridines (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Medicines Containing Plant Substances (AREA)

DK07812295T 2006-06-23 2007-06-25 Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase DK2040548T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US81595206P	2006-06-23	2006-06-23
PCT/US2007/072016 WO2007150064A2 (en)	2006-06-23	2007-06-25	METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE

Publications (1)

Publication Number	Publication Date
DK2040548T3 true DK2040548T3 (da)	2012-08-13

Family

ID=38834440

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07812295T DK2040548T3 (da)	2006-06-23	2007-06-25	Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase

Country Status (15)

Country	Link
US (4)	US7829579B2 (da)
EP (1)	EP2040548B1 (da)
JP (1)	JP5303458B2 (da)
KR (1)	KR101402554B1 (da)
AT (1)	ATE555788T1 (da)
AU (1)	AU2007260812B2 (da)
BR (1)	BRPI0713442A2 (da)
CA (1)	CA2656643C (da)
DK (1)	DK2040548T3 (da)
ES (1)	ES2387845T3 (da)
IL (1)	IL196151A (da)
MX (1)	MX2009000032A (da)
PT (1)	PT2040548E (da)
WO (1)	WO2007150064A2 (da)
ZA (1)	ZA200900270B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138262B1 (en)	2000-08-18	2006-11-21	Shire Human Genetic Therapies, Inc.	High mannose proteins and methods of making high mannose proteins
DK2040548T3 (da)	2006-06-23	2012-08-13	Amicus Therapeutics Inc	Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase
GB0622702D0 (en) *	2006-11-15	2006-12-27	Univ Dundee	Selective glycosidase inhibitors
CN104383556B (zh)	2007-05-16	2018-06-05	布里格姆妇女医院	突触核蛋白病的治疗
JP5616336B2 (ja) *	2008-06-26	2014-10-29	オルファザイムエーピーエスＯｒｐｈａｚｙｍｅＡｐｓ	酵素活性の調節因子としてのＨｓｐ７０の使用
AU2009314447A1 (en) *	2008-11-14	2010-05-20	Neuraltus Pharmaceuticals, Inc.	Compositions and methods for the treatment of altered alpha-synuclein function
JP5645918B2 (ja) *	2009-04-09	2014-12-24	アミカスセラピューティックスインコーポレイテッド	リソソーム蓄積障害の予防および／または治療方法
GB0906159D0 (en) *	2009-04-09	2009-05-20	Summit Corp Plc	Drug combination for the treatment of proteostatic diseases
CA2758187C (en) *	2009-04-09	2017-03-07	Robert Boyd	Methods for preventing and/or treating degenerative disorders of the central nervous system
US9206457B2 (en) *	2009-05-26	2015-12-08	Amicus Therapeutics, Inc.	Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
EP2435459B1 (en) *	2009-05-26	2016-05-04	Amicus Therapeutics, Inc.	Utilization of pharmacological chaperones to improve manufacturing and purification of acid beta-glucosidase
AU2010281403B2 (en) *	2009-07-28	2016-03-10	Takeda Pharmaceutical Company Limited	Compositions and methods for treating Gaucher disease
RU2015147509A (ru) *	2009-10-19	2019-01-14	Амикус Терапьютикс, Инк.	Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
WO2011049737A1 (en) *	2009-10-19	2011-04-28	Amicus Therapeutics, Inc.	Novel compositions for preventing and/or treating lysosomal storage disorders
DK2490712T3 (da) *	2009-10-19	2015-10-05	Amicus Therapeutics Inc	Fremgangsmåde til behandling af alzheimers sygdom ved anvendelse af farmakologiske chaperoner til forøgelse af aktiviteten af gangliosidaser
US9662375B2 (en)	2010-11-30	2017-05-30	Orphazyme Aps	Methods for increasing intracellular activity of Hsp70
TR201906779T4 (tr)	2011-05-12	2019-05-21	Proteostasis Therapeutics Inc	Proteostaz regülatörleri.
EP2533051A1 (en)	2011-06-06	2012-12-12	Centogene GmbH	Method for the diagnosis of Gaucher's disease
AU2012272815B2 (en) *	2011-06-22	2017-09-07	The General Hospital Corporation	Treatment of proteinopathies
WO2013112706A1 (en)	2012-01-25	2013-08-01	Proteostasis Therapeutics, Inc.	Proteasome activity modulating compounds
HK1214521A1 (zh) *	2012-11-05	2016-07-29	Genzyme Corporation	用於治療蛋白質病的組合物和方法
WO2014089449A1 (en) *	2012-12-07	2014-06-12	Rush University Nedical Center	Composition and method for treating neuronal ceroid lipofuscinosis
JP2017502961A (ja)	2013-12-23	2017-01-26	アレクトスセラピューティックスインコーポレイテッド	グルコセレブロシダーゼモジュレーターおよびその使用
US9675627B2 (en)	2014-04-14	2017-06-13	Amicus Therapeutics, Inc.	Dosing regimens for treating and/or preventing cerebral amyloidoses
US10709700B2 (en)	2014-09-15	2020-07-14	Orphazyme A/S	Arimoclomol formulation
EP3215511B1 (en)	2014-11-06	2024-04-17	Bial-R&D Investments, S.A.	Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
CA2985235A1 (en)	2015-05-07	2016-11-10	Shire Human Genetic Therapies, Inc.	Glucocerebrosidase gene therapy for parkinson's disease
KR20180133461A (ko)	2016-04-06	2018-12-14	리소소말 테라퓨틱스 인크.	피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
WO2017176961A1 (en)	2016-04-06	2017-10-12	Lysosomal Therapeutics Inc.	Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
MX388912B (es)	2016-04-06	2025-03-20	Lysosomal Therapeutics Inc	Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
WO2017178029A1 (en)	2016-04-13	2017-10-19	Orphazyme Aps	Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es)	2016-04-29	2021-06-09	Orphazyme As	Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
WO2017192930A1 (en)	2016-05-05	2017-11-09	Lysosomal Therapeutics Inc.	SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
EP3264092A1 (en) *	2016-07-01	2018-01-03	Centogene AG	Use of lyso-gb1 as druggable target
EA202091032A1 (ru) *	2017-10-26	2020-07-17	Шайр Хьюман Дженетик Терапиз, Инк.	Составы, содержащие глюкоцереброзидазу и изофагомин
CN108428452B (zh)	2018-03-14	2019-12-13	百度在线网络技术（北京）有限公司	终端支架和远场语音交互系统
WO2020006296A1 (en)	2018-06-27	2020-01-02	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
WO2020006269A1 (en)	2018-06-27	2020-01-02	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
WO2020023390A1 (en)	2018-07-25	2020-01-30	Modernatx, Inc.	Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
KR20210113606A (ko) *	2018-12-05	2021-09-16	워싱턴 유니버시티	신경 질환을 검출, 예방, 회복 및 치료하는 방법
CN113906012A (zh) *	2019-04-25	2022-01-07	武田药品工业有限公司	异法戈明盐、使用方法和调配物
CN111450306B (zh) *	2020-03-06	2021-11-19	大连理工大学	外用纳米羟基磷灰石/聚多巴胺湿黏附型止血粉及其制备方法
EP4247792A1 (en)	2020-11-19	2023-09-27	Zevra Denmark A/S	Processes for preparing arimoclomol citrate and intermediates thereof
CA3218259A1 (en) *	2021-04-30	2022-11-03	Vanqua Bio, Inc.	Small molecule modulators of glucocerebrosidase activity and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0934531B1 (en) *	1996-10-15	2004-08-04	D-Gen Limited	Diagnosis of spongiform encephalopathy
GB2355074A (en) *	1996-10-15	2001-04-11	Imperial College	Method for predicting susceptibility to bovine spongiform encephalopathy
US6274597B1 (en) *	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
JP5589165B2 (ja)	2003-01-31	2014-09-17	マウントシナイスクールオブメディシンオブニューヨークユニバーシティー	タンパク質欠損性障害の治療のための併用療法
US20050137223A1 (en)	2003-11-12	2005-06-23	Amicus Therapeutics, Inc.	Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
ES2485369T3 (es) *	2005-06-08	2014-08-13	Amicus Therapeutics, Inc.	Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas
WO2007140212A2 (en) *	2006-05-24	2007-12-06	Amicus Therapeutics, Inc.	Tartrate salt of isofagomine and methods of use
DK2040548T3 (da)	2006-06-23	2012-08-13	Amicus Therapeutics Inc	Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase
KR101789000B1 (ko) *	2007-05-22	2017-10-20	아미쿠스 세라퓨틱스, 인코포레이티드	이소파고민과 이의 유도체를 제조하는 새로운 방법

2007
- 2007-06-25 DK DK07812295T patent/DK2040548T3/da active
- 2007-06-25 JP JP2009518489A patent/JP5303458B2/ja not_active Expired - Fee Related
- 2007-06-25 PT PT07812295T patent/PT2040548E/pt unknown
- 2007-06-25 AU AU2007260812A patent/AU2007260812B2/en not_active Ceased
- 2007-06-25 MX MX2009000032A patent/MX2009000032A/es active IP Right Grant
- 2007-06-25 ES ES07812295T patent/ES2387845T3/es active Active
- 2007-06-25 US US11/768,043 patent/US7829579B2/en active Active
- 2007-06-25 KR KR1020097001465A patent/KR101402554B1/ko not_active Expired - Fee Related
- 2007-06-25 EP EP20070812295 patent/EP2040548B1/en active Active
- 2007-06-25 BR BRPI0713442-8A patent/BRPI0713442A2/pt not_active Application Discontinuation
- 2007-06-25 AT AT07812295T patent/ATE555788T1/de active
- 2007-06-25 WO PCT/US2007/072016 patent/WO2007150064A2/en not_active Ceased
- 2007-06-25 CA CA2656643A patent/CA2656643C/en not_active Expired - Fee Related
2008
- 2008-12-23 IL IL196151A patent/IL196151A/en active IP Right Grant
2009
- 2009-01-13 ZA ZA2009/00270A patent/ZA200900270B/en unknown
2010
- 2010-11-08 US US12/941,468 patent/US9119845B2/en active Active
2014
- 2014-08-26 US US14/469,008 patent/US9402837B2/en active Active
2016
- 2016-08-01 US US15/225,029 patent/US10064851B2/en active Active

Also Published As

Publication number	Publication date
IL196151A0 (en)	2009-11-18
WO2007150064A2 (en)	2007-12-27
IL196151A (en)	2015-08-31
BRPI0713442A2 (pt)	2012-03-06
US9119845B2 (en)	2015-09-01
JP5303458B2 (ja)	2013-10-02
ES2387845T3 (es)	2012-10-02
US20080009516A1 (en)	2008-01-10
CA2656643C (en)	2015-08-25
US10064851B2 (en)	2018-09-04
AU2007260812B2 (en)	2012-08-16
AU2007260812A1 (en)	2007-12-27
KR20090021393A (ko)	2009-03-03
CA2656643A1 (en)	2007-12-27
ZA200900270B (en)	2011-02-23
EP2040548A4 (en)	2009-12-23
JP2009541489A (ja)	2009-11-26
ATE555788T1 (de)	2012-05-15
EP2040548A2 (en)	2009-04-01
US20170027919A1 (en)	2017-02-02
EP2040548B1 (en)	2012-05-02
US9402837B2 (en)	2016-08-02
US7829579B2 (en)	2010-11-09
US20150025109A1 (en)	2015-01-22
WO2007150064A3 (en)	2008-02-21
MX2009000032A (es)	2009-01-23
PT2040548E (pt)	2012-08-02
US20110052613A1 (en)	2011-03-03
KR101402554B1 (ko)	2014-06-19

Publication	Publication Date	Title
ZA200900270B (en)	2011-02-23	Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase
MX2020011747A (es)	2021-01-08	Terapias genicas para los trastornos lisosomales.
MX2021012184A (es)	2022-01-24	Terapias genicas para trastornos lisosomales.
AU2018253615A1 (en)	2018-11-22	Adeno-associated virus mediated gene transfer to the central nervous system
CY1108927T1 (el)	2014-07-02	Αναστολεις μιτωτικης κινεσινης
NO20092150L (no)	2009-07-31	Fremgangsmater for behandling av hyperkolesterolemi
MX389903B (es)	2025-03-20	Enzimas de reemplazo lisosomal para usarse en el tratamiento de enfermedades de almacenamiento lisosomal.
MX354776B (es)	2018-03-20	Enzimas de reemplazo lisosomal para usarse en el tratamiento de enfermedades de almacenamiento lisosomal.
EA201170847A1 (ru)	2011-12-30	Тиазолопиридиновые соединения, регулирующие сиртуин
MX2015011943A (es)	2015-12-01	Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
MX352412B (es)	2017-11-23	Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina.
TN2010000122A1 (en)	2011-09-26	Compounds and compositions as modulators of gpr119 activity
MX2010009767A (es)	2010-09-28	Uso de celulas madre mesenquimales para tratar trastornos y enfermedades geneticas.
AR043188A1 (es)	2005-07-20	Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
AU2007257423A8 (en)	2012-02-16	Purine analogs
ATE446094T1 (de)	2009-11-15	Mitotische kinesin-hemmer
BR112013020041A2 (pt)	2016-10-25	compostos e métodos para a modulação de quinases, e indicações para os mesmos
WO2008073920A3 (en)	2009-02-26	Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2010017436A3 (en)	2010-06-17	Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
EP4707400A3 (en)	2026-05-06	Gene therapies for lysosomal disorders
SG170819A1 (en)	2011-05-30	Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
AU2009279857A8 (en)	2012-09-06	Modulation of toll-like receptor 3 expression by antisense oligonucleotides
MX2023001562A (es)	2023-05-03	Terapias genicas para trastornos lisosomales.
MX358603B (es)	2018-08-28	Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
IN2013DN11328A (da)	2015-05-15